+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID07855640

Exploring Anti-PD-1 Therapy Combined With Chemotherapy and Intraperitoneal Nab-paclitaxel as First-Line Treatment for Advanced Gastric Cancer With Malignant Ascites

Led by Zhejiang Cancer Hospital · Updated on 2026-10-02

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as a first treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma who have malignant ascites. This observational study aims to understand how effective and safe this combination is and to identify biomarkers that may predict how patients respond to treatment. The study is conducted at a single center in China and plans to enroll about 50 patients who have not received prior treatment for this condition. Participants will receive anti-PD-1 therapy along with systemic chemotherapy and intraperitoneal infusion of nab-paclitaxel. Tumor tissue, blood, and ascites samples will be collected at the start of treatment, before the second or third treatment cycle, and if the disease progresses. These samples will undergo detailed analyses including single-cell and spatial transcriptomics, proteomics, metabolomics, and flow cytometry to discover biomarkers linked to treatment response. During the study, researchers will assess treatment effectiveness by measuring the response of ascites, progression-free survival, overall survival, and safety over one year. Biomarkers in blood, tumor tissue, and ascites will be monitored for up to 24 months. Participants will be closely observed to gather data on treatment effects and side effects. The total study duration extends until July 2028, providing long-term monitoring of outcomes.

CONDITIONS

Brief Title

Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Research Team

J

Jieer Ying, Dr

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here